Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
![]()
Reuters NewMedia - Tuesday December 18, 2001
Maggie Fox, Health and Science Correspondent
They said the grim news meant that drug-resistant HIV had spread even faster than was feared, and the lifesaving cocktails of drugs that help many patients lead normal lives were becoming increasingly limited in their usefulness.
Unless better drugs are developed soon, or until a vaccine is invented that can control the virus, patients will have ever-lessening chances of using drugs to counter AIDS, the researchers told a conference sponsored by the American Society of Microbiology.
Some already have no chance at all, Dr. Douglas Richman of the Veteran's Administration hospital and the University of California in San Diego, who led the study, said.
"A number of these patients are not readily treatable," Richman said in a telephone interview.
Richman and colleagues tested blood samples taken in 1999 from 1,647 men and women. They used a test made by South San Francisco-based ViroLogic Inc. (NasdaqNM:VLGC - news) to test how the virus responded to the many available drugs used to test HIV.
"They reflect almost 209,000 people and about 130,000 who have detectable viremia (levels of virus in the blood)," Richman said.
Of these, Richman's team told the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, 78 percent carried virus that resisted at least one drug. "Just over 50 percent of them were resistant to more than one class of drugs," Richman said.
HIV EVOLVING TO RESIST DRUGS
Other studies had shown that HIV was evolving to evade nearly every drug available, but these are the most startling numbers yet.
"Many of the previous studies were relatively small and in highly selected populations, so that accurate estimates were not possible," Dr. Samuel Bozette, who worked on the study, said in a statement.
Bacteria are known to mutate to resist drugs, which is why new antibiotics are being developed regularly.
But Richman said a virus such as HIV is trickier than any bacteria. "The reason is this virus replicates to higher levels at faster rates, so it evolves faster," he said.
"Once resistance is there, it stays in a patient for the rest of his or her life. You don't get cured of an HIV species."
With bacteria, it is often possible to take a patient off antibiotics and so-called wild-type bacteria will eventually move in and push out the drug-resistant versions. Not so with HIV, which lurks in the body for decades, perhaps forever.
HIV has no cure and is always fatal, but mixes of drugs, known as highly active antiretroviral therapy (HAART) can keep patients alive and living near-normal lives for years.
There are four classes of these drugs available, each of which attacks HIV at a different point, and a mixture is required to make it work. The timing and composition of this cocktail is an art for AIDS doctors.
Richman said the study showed that doctors will have to start testing their patients right away to see if they have been infected with a resistant version of HIV.
"We have to use drugs more intelligently. This is the responsibility of physician and patient," he said. "We have to try to figure out ways to prevent transmission ... and we have to find drugs to work against resistant virus."
Preventing transmission is also difficult. Reassured by news about the success of HAART over the years, many people see HIV as a treatable illness and are indulging in risky behavior such as having unprotected sex, researchers have said.
They are ignoring advice to use condoms, despite reports in recent years that as many Americans are getting HIV as ever before and warnings that the drugs would not work forever.
"We identify two to three new (HIV) patients every week and if anything, things are getting worse," Richman said.
About 40,000 people are infected with HIV every year in the United States, with half the cases in people under 25.
011218
RE011227
Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .